ZoomInfo: Q1 Earnings Snapshot
The Vancouver, Washington-based company said it had profit of 8 cents per share. Earnings, adjusted for stock option expense and amortization costs, were 23 cents per share.
The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of 22 cents per share.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
South Korea's Celltrion says tapped to buy US pharma factory to offset tariff risk
SEOUL (Reuters) -South Korean pharmaceutical firm Celltrion said on Tuesday that in an attempt to offset the risk of U.S. tariffs it had become the preferred bidder to acquire a U.S. manufacturing factory from an unnamed global pharmaceutical company. Celltrion's Founder and Chief Executive Seo Jung-jin told a briefing it planned to invest 700 billion won ($503.78 million) in the acquisition and operation of the factory, without giving a breakdown of the figure. The company could make an additional investment ranging from 300 billion won to 700 billion won depending on U.S. tariff policy. The U.S. has been conducting a national security investigation into the pharmaceutical sector and President Donald Trump said earlier this month that pharmaceutical tariffs could be as high as 200%. He expected the tariffs to offer "opportunities" by increasing drug prices and reducing competition, thus improving profitability. Celltrion said it would not disclose further details, including the name of the seller and its location, until the signing of the final agreement, which is expected in early October.
Forbes
4 minutes ago
- Forbes
Chicago Cubs Reward Top Exec Jed Hoyer With Contract Extension
Cubs president of baseball operations Jed Hoyer received a contract extension after the Cubs' fast ... More start. (AP Photo/Kamil Krzaczynski, File) Almost nine years after eating roasted goat in left field seats at Wrigley Field the day after the Chicago Cubs won the 2016 World Series, Cubs' president of baseball operations Jed Hoyer was given more time for another bite. In the midst of the Cubs' best season since, Hoyer's job security after an underachieving four seasons is no longer an issue. The Cubs put that to bed Monday, when the sides agreed to a multi-year contract extension to replace the current five-year deal that Hoyer signed after taking over as the Cubs' president of baseball operations after Theo Epstein left following the 2020 season. The two orchestrated the moves that led the Cubs to the 2016 championship. The Cubs were tied with Milwaukee for the best record in the National League entering games of Monday, and with that management stepped in to quell any remaining uncertainty. 'Jed and his baseball operations staff have built a healthy player development organization and put an exciting, playoff-contending team on the field,' Cubs president Tom Ricketts said in a press release. 'We are looking forward to the rest of the season and to working with Jed for years to come.' The length of the extension was not announced, but it leaves no question that the other major league teams in the hunt for top executives — Washington fired World Series-winning general manager Mike Rizzo three weeks weeks ago — must look elsewhere. Hoyer signed manager Craig Counsell to a five-year, $40 million contract before last season, and pressure on Hoyer mounted when his first season ended 83-79, the same as just-fired manager David Ross. This year's turnaround has been convincing, and the new deal will give Hoyer more freedom to deal before Thursday's trade deadline, where the Cubs are targeting pitching, starters and relievers. Washington's MacKenzie Gore and Arizona's pair of Merrill Kelly and Zac Gallen are possible additions. Hoyer's Bold Move For Tucker a Winner Hoyer engineered a series of decisive moves in the offseason in an attempt get the Cubs out of the doldrums, and the industry-shaker was the trade for Kyle Tucker. Will Kyle Tucker be back? The Cubs are expected to make that a priority this winter. (AP ... More Photo/Ashley Landis) Hoyer acquired potential free agent Tucker from the Houston Astros for outfield prospect Cam Smith, productive third baseman Isaac Paredes and pitcher Hayden Weneski. It was a gamble, ongoing. The Cubs are guaranteed only one year of Tucker, whose contract expires after this season, and lost six years of Smith, one of their best minor league prospects. Smith is the Astros' right fielder and lead off hitter. Tucker has proven to be worth it. He is slashing .274/.384/.488 with 18 homers, 59 homers and 23 stolen bases. With break-out center fielder Pete Crow-Armstrong and DH Seiya Suzuki, the Cubs have one of the most potent middle-of-the order groups in the majors. The Cubs were third in the majors with 155 homers and a .769 OPS, and their run differential of plus-116 led the majors. FanGraphs gave them a 96.7 percent chance to make the postseason. Crow-Armstrong is among Hoyer's trade haul, which also included first baseman Michael Busch and shortstop Dansby Swanson. They stepped into the Japanese market by adding Suzuki and left-hander Shota Imanaga. Hoyer's next task will be to ensure that Tucker remains in Wrigley Field for the foreseeable future, the final part of the equation. (Tucker is represented by Excel Sports Management, which has Swanson among its clients.) Hoyer's Margin Calls Have Paid Off The Tucker deal made the biggest noise, but the Cubs would not be where they are without the roster pieces Hoyer added from the free agent market. Left-hander Matthew Boyd whose career has been plagued by arm injuries, has been the 11-win ace of he staff after signing a two-year, $29 million free agent contract over the winter. Right-hander Colin Rea has eight wins on a bargain one-year, $5 million deal. Boyd and Rea have been especially valuable on a staff that lost projected No. 2 starter Justin Steele to Tommy John surgery three weeks into the season and are expected to be without Jameson Taillon for a month because of a right calf injury. Catcher Carson Kelly, who signed a two-year, $11.5 million free agent deal, has 13 homers in one of the best seasons of a 10-year career. He has taken up the slack left by the of starter Miguel Amaya, who has been out since May 25.
Associated Press
4 minutes ago
- Associated Press
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
CARY, N.C., July 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ('Heron' or the 'Company'), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 11, 2025, at 4:30 p.m. ET to report second quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call. About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit Forward-looking Statements This news release contains 'forward-looking statements' as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. [email protected] 858-251-4400 View original content to download multimedia: SOURCE Heron Therapeutics, Inc.
